Several antigens expressed in melanoma cells and recognised by T cells have been identified and used in developing immunisation approaches for tumour regression
Melanoma, a malignant tumor that arises in melanocytes, is the most deadly of all skin cancers.
Although it accounts for only 4% of all skin cancer cases, melanoma is the leading cause of skin cancer deaths.
Several antigens expressed in melanoma cells and recognised by T cells have been identified and used in developing immunisation approaches for tumour regression.
These include: Mart-1/Melan-A, gp100, Tyrosinase, p15, TRP-1 and beta-catenin2.
AnaSpec, a provider of integrated proteomics solutions, offers a broad collection of peptide products for cancer research, including an extensive listing of melanoma immunodominant epitopes and their analogues.
